Abstract
We investigated the anti-tumor effect of human interferon-β (HuIFN-β) against malignant melanoma. In vitro study revealed that HuIFN-β not only inhibited proliferation of melanoma cells (seven cell lines: MM-AN, MM-BP, MM-LH, MM-RU, PM-WK, RPM-EP, RPM-MC) but also induced apoptosis in a dose dependent fashion, though the sensitivity to HuIFN-β was different among cell lines. In addition, we administered HuIFN-β into cutaneous metastatic lesions of melanoma and evaluated clinical and histopathological effects. Although the size of the metastatic cutaneous lesion did not change by the intralesional injection of HuIFN-β, histopathological examination revealed apoptotic changes of melanoma cells along with dense lymphohistiocytic infiltration. The present study confirmed direct and indirect inhibitory effects of HuIFN-β on human melanoma cells and suggests that local higher concentration of HuIFN-β is needed to eradicate melanoma lesions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Albini A, Marchisone C, Del Grosso F, Benelli R, Masiello L, Tacchetti C et al (2000) Inhibition of angiogenesis and vascular tumor growth by interferon producing cells: A gene therapy approach. Am J Pathol 156:1381–1393
Byers HR, Etoh T, Doherty RJ, Sober JA, Mihm CM Jr (1991) Cell migration and actin organization in cultured human primary, reccurent cutaneous and metastatic melanoma. Am J Pathol 139:423–435
Chawla-Sarkar M, Leaman DW, Borden EC (2001) Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2. Clin Cancer Res 7:1821–1831
Chawla-Sarkar M, Leaman DW, Jacobs BS, Borden EC (2002) IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-indeced apoptosis. J Immunol 169:847–855
Deiss LP, Feinstein E, Berissi H, Cohen O, Kimchi A (1995) Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. Genes Dev 9:15–30
Dong Z, Greene G, Pettaway C, Dinney CP, Eue I, Lu W et al (1999) Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta. Cancer Res 59:872–879
Garbe C, Krasagakis K, Zouboulis CC, Schroder K, Kruger S, Stadler R et al (1990) Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype. J Invest Dermatol 95:231s–237s
Garbe C (1993) Chomotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res 3:291–299
Hong YK, Chung DS, Joe YA, Yang YJ, Kim KM, Park YS et al (2000) Efficient inhibition in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development. Clin Cancer Res 6:3354–3360
Horikoshi T, Fukuzawa K, Hanada N, Ezoe K, Eguchi H, Hamaoka S et al (1995) In vitro comparative study of the antitumor effects of human interferon-alpha, beta, and gamma on the growth and invasive potential of human melanoma cells. J Dermatol 22:631–636
Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW (1992) Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon β. J Natl Cancer Inst 84(15):1185–1190
Kikuchi K, Nakagawa H, Kondo T, Etoh T, Byers HR, Mihm CM Jr et al (1996) Decreased ETB receptor expression in human metastatic melanoma cells. Biochem Biophys Res Commun 219:734–739
Kopf I, Hanson C, Delle U, Weimarck A, Stierner U (1996) Action of interferon alpha and beta on four human melanoma cell lines in vitro. Anticancer Res 16(2):791–798
Liu T, Biddle D, Hanks AN, Brouha B, Yan H, Lee RM et al (2006) Activation of dual apoptotic pathways in human melanocytes and protection by Survivin. J Invest Dermatol 126:2247–2256
Nagatani T, Ichiyama S, Onuma R, Miyazawa M, Matsuzaki T, Miyagawa K et al (1995) The use of DAV (DTIC, ACNU and VCR) and natural interferon-beta combination therapy in malignant melanoma. Acta Derm Venerol 75:494
Qin X Q, Runkel L, Deck C, DeDios C, Barsoum J (1997) Interferon-beta induces S phase accumulation selectively in human transformed cells. J Interferon Cytokine Res 17:355–367
Stark GR, Kerr IM, Williams BRG, Silverman RH, Schreiber RD (1998) How cells respond to interferons. Annu Rev Biochem 67:227–264
von Stamm U, Brocker EB, von Depka Prondzinski M, Ruiter DJ, Rumke P, Broding C et al (1993) Effects of systemic interferon-alpha(IFN-alpha) on the antigenic phenotype of melanoma metastases. EORTC Melanoma Group Cooperative Study No. 18852. Melanoma Res 3:173–180
Zhang H, Koty PP, Mayotte J, Levitt ML (1999) Induction of multiple programmed cell death pathways by IFN-beta in human non-small-cell lung cancer cell lines. Exp Cell Res 247:133–141
Acknowledgments
This study was supported in part by the Grant-in-Aid for Cancer Research (15–10) from the Ministry of Health, Labor and Welfare of Japan and the Grant-in-Aid for Scientific Research from the Japanese Society for the Promotion of Science, Tokyo. We thank Ryo Ogawa for his excellent technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kubo, H., Ashida, A., Matsumoto, K. et al. Interferon-β therapy for malignant melanoma: the dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells. Arch Dermatol Res 300, 297–301 (2008). https://doi.org/10.1007/s00403-008-0841-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00403-008-0841-6